AERAS [to 16 April 2016]
http://www.aeras.org/pressreleases

.
April 11, 2016
Aeras to Join the Human Vaccines Project to Accelerate Global Disease Prevention and Control
Rockville, Maryland and New York, New York,– Aeras and the Human Vaccines Project announced a new collaboration aimed at accelerating the development of vaccines and immunotherapies for key global populations.

The Human Vaccines Project is a new global initiative that brings together leading academic centers, industry, nonprofits and governments in a global discovery consortium to solve the primary scientific hurdles impeding the development of vaccines and immune-driven therapies.

“Understanding the principles of human immunity represents one of the great frontiers of science and is a key to accelerating the development of vaccines against complex diseases such as tuberculosis, HIV and malaria,” said Jacqueline E. Shea, Ph.D., Chief Executive Officer of Aeras. “The Human Vaccines Project, with its network of public and private sector partners, provides a new focus on vaccine and immunotherapeutic development.”

Under the Project’s scientific plan, a global network of leading research and development (R&D) groups will conduct extensive clinical research studies aimed at decoding the immune system, facilitated by state-of-the-art bioinformatics and machine learning. Such studies will be conducted in diverse global populations, enabling for the first time a detailed understanding of how human immunity is influenced by genetics, age and environment…

.

April 12, 2016
Biomarker Discovery Offers Hope for New TB Vaccine
Aeras is excited to share the following news release from Oxford University, about Aeras-funded research that was published today in the journal Nature Communications. We look forward to continuing our partnership with Oxford University and reaching our shared goal of developing new, effective TB vaccines.